These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25168125)

  • 1. Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes.
    Umpierrez GE; Reyes D; Smiley D; Hermayer K; Khan A; Olson DE; Pasquel F; Jacobs S; Newton C; Peng L; Fonseca V
    Diabetes Care; 2014 Nov; 37(11):2934-9. PubMed ID: 25168125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU; Plewe G; Busch K
    J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
    Zhang B; Zhao J; Yang W;
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
    Banerji MA; Baron MA; Gao L; Blonde L
    Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS).
    Misra A; Patel M; Agarwal P; Lodha S; Tandon N; Magdum M; Yajnik C; Ghosh R; Walekar A
    Diabetes Technol Ther; 2019 Nov; 21(11):656-664. PubMed ID: 31335198
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V).
    Liu J; Jiang X; Xu B; Wang G; Cui N; Zhang X; Liu J; Mu Y; Guo L
    Adv Ther; 2020 Apr; 37(4):1675-1687. PubMed ID: 32130661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5.
    Buse JB; Rodbard HW; Trescoli Serrano C; Luo J; Ivanyi T; Bue-Valleskey J; Hartman ML; Carey MA; Chang AM;
    Diabetes Care; 2016 Jan; 39(1):92-100. PubMed ID: 26577417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
    Davies M; Lavalle-González F; Storms F; Gomis R;
    Diabetes Obes Metab; 2008 May; 10(5):387-99. PubMed ID: 18355327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors.
    Blonde L; Baron MA; Zhou R; Banerji MA
    Postgrad Med; 2014 May; 126(3):172-89. PubMed ID: 24918802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
    Koivisto V; Cleall S; Pontiroli AE; Giugliano D
    Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
    Riddle MC; Bolli GB; Ziemen M; Muehlen-Bartmer I; Bizet F; Home PD;
    Diabetes Care; 2014 Oct; 37(10):2755-62. PubMed ID: 25078900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes.
    Smiley D; Umpierrez GE; Hermayer K; Newton C; Jacobs S; Olson DE; Khan A; Rizzo M; Peng L; Reyes D; Cardona S; Fonseca V
    J Diabetes Complications; 2013; 27(6):637-41. PubMed ID: 23911535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.
    Owens DR; Traylor L; Dain MP; Landgraf W
    Diabetes Res Clin Pract; 2014 Nov; 106(2):264-74. PubMed ID: 25195151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Post-hoc analyses of type 2 diabetes patients switch from premixed insulin regimen to basal insulin plus oral hypoglycemic agents regimen].
    Bu S; Guo XH; Yang WY; Lu GZ; Yang ZJ; Ren TT; Gao Y
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3115-8. PubMed ID: 18269868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
    Yki-Järvinen H; Bergenstal R; Ziemen M; Wardecki M; Muehlen-Bartmer I; Boelle E; Riddle MC;
    Diabetes Care; 2014 Dec; 37(12):3235-43. PubMed ID: 25193531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.